April 2016 in “Journal of Investigative Dermatology”
Tumor cell adhesion is linked to higher risk of SLN metastasis and melanoma recurrence, and a model including these factors predicts these outcomes better than one with just clinical data.
Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.
A 42-year-old male shared his 1.5-year hair regrowth progress using 1.25mg finasteride daily and regular doses of minoxidil twice a day, and recently started using the Derminator 2. He also mentioned his battle with cancer and Cushing's syndrome, which affected his weight and hair.
The user experienced severe side effects from finasteride, including hormonal imbalances and cognitive issues, leading to a recommendation to stop its use. They plan to follow up with tests to rule out a pituitary tumor and are considering topical treatments as alternatives.
RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.